T. Kim

Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

Background In the phase 3, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab versus chemotherapy provided superior progression-free survival (PFS) at second interim a...

J. Bendell ;

D. Le ;

Takayuki Yoshino , MD, PhD;

W. Zhong ;

T. Andre ;

D. Fogelman ;

K. Shiu ;

P. Marinello ;

T. Kim ;

L. Diaz ;

B. Jensen ;

L. Jensen ;

C. Punt ;

D. Smith ;

Rocio Garcia-Carbonero , MD, PhD;

J. Garcia Alcaide ;

P. Gibbs ;

C. De la Fouchardiere ;

F. Herrero Rivera ;

E. Elez ;

07/02/2021

Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer

Background The PD-1 inhibitor pembrolizumab has shown robust clinical activity in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H)...

M. Gumus ;

J. Bae Ahn ;

L. Wyrwicz ;

M. Kwiatkowski ;

J. Kim ;

S. Yalcin ;

M. Sendur ;

A. Odeleye-Ajakaye ;

P. Leconte ;

T. Andre ;

T. Kim ;

D. Fogelman ;

C. Sposetti ;

06/27/2022

Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy

BackgroundLong-term responders to ICI occur in advanced HCC pts; though little is known about ultimate outcomes and treatment trajectory. A clinical knowledge gap exists for long-term dis...

R. Do ;

S. Folorunso ;

I. El Dika ;

A. Yaqubie ;

E. O'Reilly ;

J. Harding ;

T. Kim ;

D. Cowzer ;

F. Keane ;

D. Khalil ;

J. Shia ;

06/25/2023